EYENOVIA INC (EYEN)

US30234E1047 - Common Stock

0.0853  0 (-5.22%)

After market: 0.0868 +0 (+1.76%)

Fundamental Rating

1

Taking everything into account, EYEN scores 1 out of 10 in our fundamental rating. EYEN was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EYEN have multiple concerns. EYEN is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EYEN has reported negative net income.
EYEN had a negative operating cash flow in the past year.
In the past 5 years EYEN always reported negative net income.
EYEN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

EYEN has a worse Return On Assets (-165.95%) than 86.91% of its industry peers.
EYEN has a Return On Equity of -1017.15%. This is amonst the worse of the industry: EYEN underperforms 84.82% of its industry peers.
Industry RankSector Rank
ROA -165.95%
ROE -1017.15%
ROIC N/A
ROA(3y)-75.11%
ROA(5y)-85.52%
ROE(3y)-175.98%
ROE(5y)-167.48%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

EYEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

EYEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EYEN has been increased compared to 1 year ago.
The number of shares outstanding for EYEN has been increased compared to 5 years ago.
The debt/assets ratio for EYEN is higher compared to a year ago.

2.2 Solvency

EYEN has an Altman-Z score of -16.00. This is a bad value and indicates that EYEN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EYEN (-16.00) is worse than 81.68% of its industry peers.
A Debt/Equity ratio of 0.58 indicates that EYEN is somewhat dependend on debt financing.
EYEN has a Debt to Equity ratio of 0.58. This is in the lower half of the industry: EYEN underperforms 65.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z -16
ROIC/WACCN/A
WACC13.09%

2.3 Liquidity

EYEN has a Current Ratio of 0.74. This is a bad value and indicates that EYEN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.74, EYEN is doing worse than 93.72% of the companies in the same industry.
A Quick Ratio of 0.55 indicates that EYEN may have some problems paying its short term obligations.
EYEN has a Quick ratio of 0.55. This is amonst the worse of the industry: EYEN underperforms 93.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.55

More info and screens

4

3. Growth

3.1 Past

EYEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.61%.
The Revenue for EYEN have been decreasing by -87.63% on average. This is quite bad
EPS 1Y (TTM)-10.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.89%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-87.63%
Revenue growth 5YN/A
Sales Q2Q%66.67%

3.2 Future

Based on estimates for the next years, EYEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.73% on average per year.
Based on estimates for the next years, EYEN will show a very strong growth in Revenue. The Revenue will grow by 168.85% on average per year.
EPS Next Y9.42%
EPS Next 2Y16.97%
EPS Next 3Y14.6%
EPS Next 5Y15.73%
Revenue Next Year103.02%
Revenue Next 2Y218.92%
Revenue Next 3Y248.29%
Revenue Next 5Y168.85%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EYEN. In the last year negative earnings were reported.
Also next year EYEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

EYEN's earnings are expected to grow with 14.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.97%
EPS Next 3Y14.6%

More info and screens

0

5. Dividend

5.1 Amount

EYEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EYENOVIA INC

NASDAQ:EYEN (12/20/2024, 8:07:59 PM)

After market: 0.0868 +0 (+1.76%)

0.0853

0 (-5.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners13.6%
Inst Owner Change15%
Ins Owners9.99%
Ins Owner Change10.13%
Market Cap9.50M
Analysts78
Price Target3.32 (3792.15%)
Short Float %6.55%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.07%
Min EPS beat(2)-37.25%
Max EPS beat(2)19.12%
EPS beat(4)1
Avg EPS beat(4)-12.08%
Min EPS beat(4)-37.25%
Max EPS beat(4)19.12%
EPS beat(8)5
Avg EPS beat(8)0.69%
EPS beat(12)6
Avg EPS beat(12)11.7%
EPS beat(16)10
Avg EPS beat(16)12.43%
Revenue beat(2)0
Avg Revenue beat(2)-98.19%
Min Revenue beat(2)-98.79%
Max Revenue beat(2)-97.58%
Revenue beat(4)0
Avg Revenue beat(4)-98.48%
Min Revenue beat(4)-99.52%
Max Revenue beat(4)-97.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.47%
PT rev (3m)-70%
EPS NQ rev (1m)7.99%
EPS NQ rev (3m)56.93%
EPS NY rev (1m)7.99%
EPS NY rev (3m)12.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.65%
Revenue NY rev (1m)-53.93%
Revenue NY rev (3m)-53.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 298.52
P/FCF N/A
P/OCF N/A
P/B 2.56
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS0.03
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -165.95%
ROE -1017.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.11%
ROA(5y)-85.52%
ROE(3y)-175.98%
ROE(5y)-167.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28%
Cap/Sales 970.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.74
Quick Ratio 0.55
Altman-Z -16
F-Score3
WACC13.09%
ROIC/WACCN/A
Cap/Depr(3y)460.2%
Cap/Depr(5y)498.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.89%
EPS Next Y9.42%
EPS Next 2Y16.97%
EPS Next 3Y14.6%
EPS Next 5Y15.73%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-87.63%
Revenue growth 5YN/A
Sales Q2Q%66.67%
Revenue Next Year103.02%
Revenue Next 2Y218.92%
Revenue Next 3Y248.29%
Revenue Next 5Y168.85%
EBIT growth 1Y-57.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-157.15%
EBIT Next 3Y50.91%
EBIT Next 5Y40.74%
FCF growth 1Y-15.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.64%
OCF growth 3YN/A
OCF growth 5YN/A